Platinum-based drugs: past, present and future

By S. Dilruba, G. Kalayda. Cancer Chemotherapy and Pharmacology, 2016

752 citations recorded by the source corpus.

Subfields: Hematology, Materials Chemistry, Oncology

View Paper: https://www.semanticscholar.org/paper/41b7f9ba3ea039b17be136cf021d9a79b8a72622

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Materials Chemistry

1. A. Hughes

In Oncology

1. Xueyun Gao
2. Chao Xu
3. Chunyu Zhang
4. Qingqiang Yao

Citations in the corpus

• Platinum-based drugs for cancer therapy and anti-tumor strategies (2022, background): “Compared with cisplatin, carboplatin exhibits a lower hydration rate due to the bidentate cyclobutane dicarboxylic acid ligands [32, 33] and has high biosafety with greatly reduced systemic toxicity, including hepatotoxicity, nephrotoxicity, neurotoxicity, and ototoxicity [34].”
• Platinum Group Metals: A Review of Resources, Production and Usage with a Focus on Catalysts (2021, background): “The medical sector also includes the use of PGM catalysts for the manufacture of pharmaceuticals [85].”